Back to search
Paraneoplastic Neurological Syndromes
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Paraneoplastic Neurological Syndromes trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Paraneoplastic Neurological Syndromes trials you may qualify forThis study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safe…
This study is an open-label, exploratory, prospective clinical trial with dose escalation(according to "3+3" design), to evaluate the safety and tolerability of…
The main objective of the study is to assess whether circulating tumor cells (CTCs) can be detected in the peripheral blood of patients with paraneoplastic neur…
The aim of this project is to improve biological collections of patients presenting rare neurological disorders with known or suspected autoimmune origin. This…
A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gra…
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclero…
This phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a stem cel…
This is an open label, single-site, dose-escalation study in up to 15 participants with relapsed or refractory Neurological Autoimmune Diseases. This study aims…